CAMBRIDGE, Mass., May 12, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced today the appointment of Nic G. Scalfarotto, D.V.M., Vice President of Regulatory Affairs. Prior to joining Momenta, Dr. Scalfarotto was most recently a Principal at Strategic Regulatory Consulting, L.L.C., where he provided contractual and consultative regulatory services to pharmaceutical, biotechnology, and other related industries, and Vice President, Global Regulatory Affairs and Clinical Quality Assurance at Eurand Pharmaceuticals, Inc.
Dr. Scalfarotto's past positions also include Group Director of Global Regulatory Sciences at Bristol-Myers Squibb, Inc, Therapeutic Head, Metabolism and Endocrinology and Director of Worldwide Regulatory Affairs at Millennium Pharmaceuticals, Vice President of Regulatory Affairs at Parexel International, and General Management roles, leading preclinical development divisions, for companies such as Oread, Inc., and Chrysalis International.
"Nic has nearly three decades of drug development and regulatory affairs leadership across a spectrum of large pharmaceutical and biotechnology companies, and contract research organizations. Notably, he also has expertise in several therapeutic areas with both small molecules and biologics, and has led creative and productive interactions with many divisions within FDA," commented Jim Roach M.D., Chief Medical Officer of Momenta. "The breadth, depth and relevance of Nic's experience is very well suited to Momenta's diverse product portfolio."
Dr. Scalfarotto received his D.V.M. from the University of Bologna in Italy, and his B.S. from Seton Hall University.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
CONTACT: Momenta Pharmaceuticals, Inc. Beverly Holley Director, Investor Relations 617-395-5189 bholley@momentapharma.com